Recent Advances in Nanoparticle-Based Nuclear Imaging of Cancers

Srivatsan, Avinash; Chen, Xiaoyuan

doi:10.1016/b978-0-12-411638-2.00003-3

Cited by 34 publications

(25 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomes can be radiolabeled during preparation by (1) passive encapsulation of the radionuclide or by (2) labeling of the liposomal membranes. After preparation of the liposomes, the preformed liposomes can be radiolabeled by (3) loading of the radionuclide into liposomes either via an ionophore, using a lipophilic chelator, or by labeling the liposomal surface after inclusion of a chelator on the surface of the liposomes [36].…”

Section: Radiolabeling Of Liposomesmentioning

confidence: 99%

Radionuclide imaging of liposomal drug delivery

Geest

Laverman

Metselaar

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction: Ever since their discovery, liposomes have been radiolabeled to monitor their fate in vivo. Despite extensive preclinical studies, only a limited number of radiolabeled liposomal formulations have been examined in patients. Since they can play a crucial role in patient management, it is of importance to enable translation of radiolabeled liposomes into the clinic.Areas covered: Liposomes have demonstrated substantial advantages as drug delivery systems and can be efficiently radiolabeled. Potentially, radiolabeled drug-loaded liposomes form an elegant theranostic system, which can be tracked in vivo using single-photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging. In this review, we discuss important aspects of liposomal research with a focus on the use of radiolabeled liposomes and their potential role in drug delivery and monitoring therapeutic effects. Expert opinion: Radiolabeled drug-loaded liposomes have been poorly investigated in patients and no radiolabeled liposomes have been approved for use in clinical practice. Evaluation of the risks, pharmacokinetics, pharmacodynamics and toxicity is necessary to meet pharmaceutical and commercial requirements. It remains to be demonstrated whether the results found in animal studies translate to humans before radiolabeled liposomes can be implemented into clinical practice. ARTICLE HISTORY

show abstract

Section: Radiolabeling Of Liposomesmentioning

confidence: 99%

Radionuclide imaging of liposomal drug delivery

Geest

Laverman

Metselaar

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Apart from the application in cancer diagnosis, there has been a great interest in developing new nanomaterials for cancer treatment. 20,21 Poly (d,l-lactide-co-glycolide) (PLGA), a biodegradable and biocompatible synthetic polymer approved by the US Food and Drug Administration, is widely used in drug delivery system. [22][23][24] Various studies have reported that multiple drug resistance could be overcome by PLGA NPs codelivering anticancer drug and p-gp inhibitors, indicating that PLGA NPs may be a promising approach to overcome drug resistance.…”

Section: Introductionmentioning

confidence: 99%

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Ji¹,

Chen²,

Bao³

et al. 2016

IJN

View full text Add to dashboard Cite

Drug resistance has become a main obstacle for the effective treatment of lung cancer. To address this problem, a novel biocompatible nanoscale package, poly( d , l -lactide- co -glycolide)-Tween 80, was designed and synthesized to overcome paclitaxel (PTX) resistance in a PTX-resistant human lung cancer cell line. The poly( d , l -lactide-co-glycolide) (PLGA)-Tween 80 nanoparticles (NPs) could efficiently load PTX and release the drug gradually. There was an increased level of uptake of PLGA-Tween 80 in PTX-resistant lung cancer cell line A549/T, which achieved a significantly higher level of cytotoxicity than both PLGA NP formulation and Taxol ® . The in vivo antitumor efficacy also showed that PLGA-Tween 80 NP was more effective than Taxol ® , indicating that PLGA-Tween 80 copolymer was a promising carrier for PTX in resistant lung cancer.

show abstract

“…5 Since the positrons rapidly lose their kinetic energy, the point of γ-ray emission stays typically within a fraction of a millimeter around the location of the tracer molecules. To avoid radiation damage to the patient, common PET tracers have short half-lives (ie, approximately 20 minutes for 11 C and 110 minutes for 18 F). Consequently, the radioisotopes must be generated onsite and quickly administered to the subject before they decay.…”

Section: Introductionmentioning

confidence: 99%

“…9 Over the last decade, several nanoparticle formulations have been developed for radionuclide imaging with the aim of enhancing the sensitivity and identification of specific targets. 10,11 Therefore, nanocarriers loaded with radionuclides may offer an elegant and novel possibility for harnessing this promising technology.…”

Section: Introductionmentioning

confidence: 99%

Sodium-22-radiolabeled silica nanoparticles as new radiotracer for biomedical applications: in vivo positron emission tomography imaging, biodistribution, and biocompatibility

Faraj¹,

Al‐Otaibi²,

Shaik³

et al. 2015

IJN

View full text Add to dashboard Cite

Despite their advantageous chemical properties for nuclear imaging, radioactive sodium-22 ( 22 Na) tracers have been excluded for biomedical applications because of their extremely long lifetime. In the current study, we proposed, for the first time, the use of 22 Na radiotracers for pre-clinical applications by efficiently loading with silica nanoparticles (SiNPs) and thus offering a new life for this radiotracer. Crown-ether-conjugated SiNPs (300 nm; −0.18±0.1 mV) were successfully loaded with 22 Na with a loading efficacy of 98.1%±1.4%. Noninvasive positron emission tomography imaging revealed a transient accumulation of 22 Na-loaded SiNPs in the liver and to a lower extent in the spleen, kidneys, and lung. However, the signal gradually decreased in a time-dependent manner to become not detectable starting from 2 weeks postinjection. These observations were confirmed ex vivo by quantifying 22 Na radioactivity using γ-counter and silicon content using inductively coupled plasma-mass spectrometry in the blood and the different organs of interest. Quantification of Si content in the urine and feces revealed that SiNPs accumulated in the organs were cleared from the body within a period of 2 weeks and completely in 1 month. Biocompatibility evaluations performed during the 1-month follow-up study to assess the possibility of synthesized nanocarriers to induce oxidative stress or DNA damage confirmed their safety for pre-clinical applications. 22 Na-loaded nanocarriers can thus provide an innovative diagnostic agent allowing ultra-sensitive positron emission tomography imaging. On the other hand, with its long lifetime, onsite generators or cyclotrons will not be required as 22 Na can be easily stored in the nuclear medicine department and be used on-demand.

show abstract

Recent Advances in Nanoparticle-Based Nuclear Imaging of Cancers

Cited by 34 publications

References 155 publications

Radionuclide imaging of liposomal drug delivery

Radionuclide imaging of liposomal drug delivery

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Sodium-22-radiolabeled silica nanoparticles as new radiotracer for biomedical applications: in vivo positron emission tomography imaging, biodistribution, and biocompatibility

Contact Info

Product

Resources

About